DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
DexCom Stock Performance
DexCom stock opened at $70.69 on Friday. The firm has a 50 day simple moving average of $83.99 and a 200-day simple moving average of $76.85. The stock has a market cap of $27.62 billion, a price-to-earnings ratio of 49.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.
DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.
Institutional Trading of DexCom
Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Covestor Ltd increased its position in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock valued at $64,000 after acquiring an additional 335 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company's stock worth $1,259,000 after purchasing an additional 182 shares during the period. Harbour Investments Inc. increased its holdings in DexCom by 8.8% in the 3rd quarter. Harbour Investments Inc. now owns 12,895 shares of the medical device company's stock valued at $864,000 after purchasing an additional 1,046 shares during the last quarter. GSA Capital Partners LLP raised its position in DexCom by 129.1% in the third quarter. GSA Capital Partners LLP now owns 10,268 shares of the medical device company's stock valued at $688,000 after purchasing an additional 5,787 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in DexCom during the third quarter worth $221,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
DXCM has been the topic of several research analyst reports. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Morgan Stanley increased their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.82.
Read Our Latest Stock Analysis on DXCM
DexCom Company Profile
(
Get Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
